BlackRock, Inc. filed a Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 1,384,230 shares of Precision Biosciences Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported holding 1,384,230 shares of Precision Biosciences Inc. common stock, representing 5.01% of the class.
  • Sole voting power: BlackRock disclosed sole voting power over 1,349,236 shares, with no shared voting power reported.
  • Sole dispositive power: BlackRock reported sole dispositive power over all 1,384,230 shares, with no shared dispositive power reported.
  • Filing trigger date: The event requiring this filing occurred on September 30, 2026.
  • Filer classification: BlackRock identified itself as a parent holding company (type "HC"), organized in Delaware, with its principal office at 50 Hudson Yards, New York, NY 10001.
  • Dividend/proceeds rights: According to the filing, various persons have the right to receive dividends or proceeds from the sale of the common stock, but no single person's interest exceeds five percent of total outstanding shares.

BlackRock's Schedule 13G Filing on Precision Biosciences Common Stock

BlackRock, Inc., acting as a parent holding company, filed a Schedule 13G on October 27, 2026, reporting beneficial ownership in Precision Biosciences Inc. (CUSIP 74019P207), a company headquartered at 302 East Pettigrew Street, Suite A-100, Durham, NC 27701. The filing was triggered by an event dated September 30, 2026, and was signed by Spencer Fleming, Managing Director of BlackRock.

According to the filing, BlackRock's aggregate beneficial ownership stands at 1,384,230 shares of common stock, equal to 5.01% of the class. Of that total, BlackRock reported sole voting power over 1,349,236 shares and sole dispositive power over the full 1,384,230 shares. The filing states that both shared voting power and shared dispositive power are zero.

The filing notes, in accordance with SEC Release No. 34-39538 dated January 12, 1998, that the reported holdings reflect securities beneficially owned by certain business units of BlackRock and its subsidiaries and affiliates, collectively described as the "Reporting Business Units." The filing also states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The identity and classification of the relevant subsidiary are provided in Exhibit 99 attached to the filing.

What Was Disclosed

BlackRock, Inc. disclosed a 5.01% beneficial ownership stake in Precision Biosciences Inc. common stock, totaling 1,384,230 shares, with sole dispositive power over all reported shares and sole voting power over 1,349,236 shares, as of September 30, 2026.